NCT02673151View on ClinicalTrials.gov

68Ga-PSMA PET/CT in Detecting Prostate Cancer Recurrence in Patients With Elevated PSA After Initial Treatment

PHASE2/PHASE3CompletedINTERVENTIONAL
Enrollment

61

Participants

Timeline

Start Date

May 20, 2017

Primary Completion Date

April 27, 2018

Study Completion Date

April 27, 2019

Conditions
Prostate AdenocarcinomaPSA FailureRecurrent Prostate Carcinoma
Interventions
PROCEDURE

Computed Tomography (CT) scan

PET/CT scan using 68gallium-labeled prostate-specific membrane antigen-11 (68-Ga-PSMA-11).

DRUG

68Ga-PSMA-11

68gallium-labeled prostate-specific membrane antigen-11 (68-Ga-PSMA-11), administered by intravenous (IV) injection.

PROCEDURE

Positron Emission Tomography (PET)

PET/CT scan using 68gallium-labeled prostate-specific membrane antigen-11 (68-Ga-PSMA-11).

Trial Locations (1)

94304

Stanford University, School of Medicine, Palo Alto

All Listed Sponsors
lead

Andrei Iagaru

OTHER

NCT02673151 - 68Ga-PSMA PET/CT in Detecting Prostate Cancer Recurrence in Patients With Elevated PSA After Initial Treatment | Biotech Hunter | Biotech Hunter